Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jimd.70080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Migalastat Use in Fabry Disease: Comparative Insights From the Pisani and Hughes Studies.
J Inherit Metab Dis
September 2025
Department of Public Health, Chair of Nephrology, University Federico II of Naples, Naples, Italy.
Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.
J Clin Med
July 2025
Global Evidence and Outcomes, Data and Quantitative Sciences Institute, Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA.
This systematic literature review aimed to identify studies assessing the clinical efficacy and real-world effectiveness of current and emerging treatments for Fabry disease. Searches of the MEDLINE, EMBASE, and Cochrane library databases, as well as relevant congress proceedings, were conducted to identify publications reporting on studies in patients of any age, sex, race, or ethnicity who received any approved or experimental treatment for Fabry disease, published before 17 June 2024. Of 1881 publications screened, 234 reported data on renal, cardiac, cerebrovascular, and disease severity outcomes from 225 studies.
View Article and Find Full Text PDFEffects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice.
Adv Ther
February 2025
Cardiovascular Department, ASL8 Arezzo San Donato Hospital, Via Pietro Nenni 20, 52100, Arezzo, Italy.
Article Synopsis
- - Fabry disease (FD) is a rare genetic disorder causing issues in the kidneys, nervous system, and heart, with four treatment options: three enzyme replacement therapies (ERTs) and one pharmacological chaperone.
- - Agalsidase beta and agalsidase alfa improve various organ functions and quality of life, with agalsidase beta possibly being more effective long-term; early treatment is crucial for optimal response.
- - Migalastat benefits patients with specific gene variants by stabilizing kidney function and relieving some symptoms, but its neurological effects are unclear and further research is needed for direct treatment comparisons.
Influence of Treatment Effect Modifiers in Fabry Disease: A Systematic Literature Review.
Adv Ther
February 2025
Cytel, Inc., Waltham, MA, USA.
Article Synopsis
- Fabry disease (FD) is a rare metabolic disorder with varying symptoms, making it essential to identify patient characteristics that affect treatment outcomes due to a lack of direct treatment comparisons.
- A systematic literature review (SLR) was performed to analyze real-world evidence from 119 studies, revealing potential treatment effect modifiers (TEMs) such as age, sex, timing of treatment, and renal function.
- Key findings included that males tend to have poorer renal outcomes, younger patients benefit more from early treatment, and factors like left ventricular hypertrophy and baseline kidney function significantly influence disease progression and treatment efficacy.
Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registry.
J Inherit Metab Dis
January 2025
University Hospital Würzburg, Würzburg, Germany.
Fabry disease is a progressive, X-linked lysosomal disorder caused by reduced or absent α-galactosidase A activity due to GLA variants. The effects of migalastat were examined in a cohort of 125 Fabry patients with migalastat-amenable GLA variants in the followME Pathfinders registry (EUPAS20599), an ongoing, prospective, patient-focused registry evaluating outcomes for current Fabry disease treatments. We report annualised estimated glomerular filtration rate (eGFR) and Fabry-associated clinical events (FACEs) in a cohort of patients who had received ≥3 years of migalastat treatment in a real-world setting.
View Article and Find Full Text PDF